Cue Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary

• Cue Biopharma Inc CUE.OQ reported a quarterly adjusted loss of 17 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -25 cents. The mean expectation of three analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -18 cents to -13 cents per share.

• Revenue fell 75.5% to $421.00 thousand from a year ago; analysts expected $1.27 million.

• Cue Biopharma Inc's reported EPS for the quarter was a loss of 17 cents​.

• The company reported a quarterly loss of $12.26 million.

• Cue Biopharma Inc shares had fallen by 17.6% this quarter and lost 31.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Cue Biopharma Inc is $3.00

This summary was machine generated from LSEG data May 13 at 06:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)